Ad5-yCD/mutTK(SR39)rep-ADP
Alternative Names: Ad5-CD/TKrep; Ad5-yCD/mutTKSR39rep-ADP; Ad5-yCD/mutTKSR39rep-hIL12; Radiation-sensitising gene therapy - NewGenPharm/Henry Ford Health System; TherageneLatest Information Update: 20 Jan 2023
Price :
$50 *
At a glance
- Originator Henry Ford Health System
- Developer Henry Ford Health System; NewGenPharm
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- Phase I Astrocytoma
- No development reported Prostate cancer
Most Recent Events
- 29 Nov 2022 Phase-I clinical trials in Astrocytoma (Late-stage disease, Recurrent) in USA (Intratumoural) (NCT05686798)
- 31 Mar 2021 Hengry Ford Health System filed has patent pending for methods, composition involved in Ad5-yCD/mutTK(SR39)rep-ADP in USA by March 2021
- 17 Mar 2021 Phase-II clinical trials in Pancreatic cancer (Late-stage disease, Adjunctive treatment) in South Korea (Parenteral) (NCT04739046)